UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019129
Receipt number R000022115
Scientific Title Analyses of immune status of patients with gastrointestinal cancer
Date of disclosure of the study information 2015/09/27
Last modified on 2023/10/03 09:46:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Analyses of immune status of patients with gastrointestinal cancer

Acronym

Immune monitoring in GI cancer

Scientific Title

Analyses of immune status of patients with gastrointestinal cancer

Scientific Title:Acronym

Immune monitoring in GI cancer

Region

Japan


Condition

Condition

Gastrointestinal cancer

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the profile of immune cells and immune factors in tumor tissue or peripheral blood

Basic objectives2

Others

Basic objectives -Others

To evaluate relationship between immune profile and clinicopatholigical features as well as treatment response and prognosis

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

immune profile in gastrointestinal cancers

Key secondary outcomes

Association between immune profile and clinicopatholigical features as well as treatment response and prognosis


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with histologically confirmed or clinically suspected advanced cancer or malignant tumor of following descriptions; 1.gastric cancer 2.Esophageal cancer 3.colorectal cancer 4. GIST
2) Planned to receive surgery or systemic chemotherapy (one or more enrollment is possible per patient)
3) Plan to acquire sufficient tumor materials or sufficient archival materials to analyze
4) Written informed consent was obtained

Key exclusion criteria

1) Patient is judged by the investigator to be inappropriate for study participation for any reason.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Hiroyoshi
Middle name
Last name Nishikawa

Organization

National Cancer Center Hospital East

Division name

EPOC TR department

Zip code

277-8577

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

TEL

04-7133-1111

Email

hnishika@east.ncc.go.jp


Public contact

Name of contact person

1st name Kohei
Middle name
Last name Shitara

Organization

National Cancer Center Hospital East

Division name

Gastrointestinal Oncology Division

Zip code

277-8577

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

TEL

04-7133-1111

Homepage URL


Email

kshitara@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center Hospital East

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB in National Cancer Center Hospital

Address

Tsukiji 5-1-1

Tel

03-3542-2511

Email

NCC_IRBoffice@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 09 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2015 Year 09 Month 11 Day

Date of IRB

2015 Year 09 Month 17 Day

Anticipated trial start date

2015 Year 09 Month 17 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective observational study. Patients who met eligibility criteria with written informed consent will be enrolled since Sep. 2015. Immune profile will be evaluated in serum and tumor samples.


Management information

Registered date

2015 Year 09 Month 27 Day

Last modified on

2023 Year 10 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022115


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name